 |
|
Ondansetron for Reduction of Drinking Among Biologically Predisposed Alcoholic Patients
A Randomized Controlled Trial
Bankole A. Johnson, MD, PhD;
John D. Roache, PhD;
Martin A. Javors, PhD;
Carlo C. DiClemente, PhD;
Claude Robert Cloninger, MD;
Thomas J. Prihoda, PhD;
Patrick S. Bordnick, PhD;
Nassima Ait-Daoud, MD;
Julie Hensler, PhD
JAMA. 2000;284:963-971.
Context Early-onset alcoholism differs from late-onset alcoholism by its association with greater serotonergic abnormality and antisocial behaviors. Thus, individuals with early-onset alcoholism may be responsive to treatment with a selective serotonergic agent.
Objective To test the hypothesis that drinking outcomes associated with early vs late-onset alcoholism are differentially improved by the selective 5-HT3 (serotonin) antagonist ondansetron.
Design Double-blind, randomized, placebo-controlled clinical trial.
Settings University of Texas Health Science Center in Houston (April 1995-June 1998) and University of Texas Health Science Center in San Antonio (July 1998-December 1999).
Participants A total of 321 patients with diagnosed alcoholism (mean age, 40.6 years; 70.5% male; 78.6% white) were enrolled, 271 of whom proceeded to randomization.
Interventions After 1 lead-in week of single-blind placebo, patients were randomly assigned to receive 11 weeks of treatment with ondansetron, 1 µg/kg (n = 67), 4 µg/kg (n = 77), or 16 µg/kg (n = 71) twice per day; or identical placebo (n = 56). All patients also participated in weekly standardized group cognitive behavioral therapy.
Main Outcome Measures Self-reported alcohol consumption (drinks per day, drinks per drinking day, percentage of days abstinent, and total days abstinent per study week); and plasma carbohydrate deficient transferrin (CDT) level, an objective and sensitive marker of transient alcohol consumption.
Results Patients with early-onset alcoholism who received ondansetron (1, 4, and 16 µg/kg twice per day) compared with those who were administered placebo, had fewer drinks per day (1.89, 1.56, and 1.87 vs 3.30; P = .03, P = .01, and P = .02, respectively) and drinks per drinking day (4.75, 4.28, and 5.18 vs 6.90; P = .03, P = .004, and P = .03, respectively). Ondansetron, 4 µg/kg twice per day, was superior to placebo in increasing percentage of days abstinent (70.10 vs 50.20; P = .02) and total days abstinent per study week (6.74 vs 5.92; P = .03). Among patients with early-onset alcoholism, there was a significant difference in the mean log CDT ratio between those who received ondansetron (1 and 4 µg/kg twice per day) compared with those who received the placebo (-0.17 and -0.19 vs 0.12; P = .03 and P = .01, respectively).
Conclusion Our results suggest that ondansetron (particularly the 4 µg/kg twice per day dosage) is an effective treatment for patients with early-onset alcoholism, presumably by ameliorating an underlying serotonergic abnormality.
Author Affiliations: Department of Psychiatry, University of Texas Health Science Center, San Antonio (Drs Johnson, Roache, Javors, Prihoda, Bordnick, Ait-Daoud, and Hensler); Department of Psychology, University of Maryland, Baltimore (Dr DiClemente); and School of Medicine, Washington University, St Louis, Mo (Dr Cloninger).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Medications for Alcohol Dependence--New Vistas
JAMA. ;284():1016-1017.
FULL TEXT
August 23, 2000
JAMA. ;284():1035-1036.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel
Physiol. Rev. 2009;89:649-705.
ABSTRACT
| FULL TEXT
The Alcoholic Phenotypes among Different Multidimensional Typologies: Similarities and Their Classification Procedures
Pombo and Lesch
Alcohol Alcohol 2009;44:46-54.
ABSTRACT
| FULL TEXT
Evidence-based treatments of addiction
O'Brien
Phil Trans R Soc B 2008;363:3277-3286.
ABSTRACT
| FULL TEXT
Invited Commentary * Serotonin transporter (SERT) brain density and neurobiological cloninger subtypes model: a lesson by human autoradiography studies
Leggio and Addolorato
Alcohol Alcohol 2008;43:148-150.
ABSTRACT
| FULL TEXT
Subunit-Dependent Modulation of the 5-Hydroxytryptamine Type 3 Receptor Open-Close Equilibrium by n-Alcohols
Rusch et al.
J. Pharmacol. Exp. Ther. 2007;321:1069-1074.
ABSTRACT
| FULL TEXT
Association of a Functional Polymorphism in the {micro}-Opioid Receptor Gene With Alcohol Response and Consumption in Male Rhesus Macaques
Barr et al.
Arch Gen Psychiatry 2007;64:369-376.
ABSTRACT
| FULL TEXT
Emerging approaches to managing alcohol dependence
SWIFT
Am J Health Syst Pharm 2007;64:S12-S22.
ABSTRACT
| FULL TEXT
Preclinical Development and Clinical Implementation of Treatments for Substance Abuse Disorders
Pechnick et al.
Focus 2007;5:151-162.
ABSTRACT
| FULL TEXT
Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth
Wilens and Biederman
J Psychopharmacol 2006;20:580-588.
ABSTRACT
Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O'Brien
Am. J. Psychiatry 2005;162:1423-1431.
ABSTRACT
| FULL TEXT
SEQUENTIALLY ADJUSTED RANDOMIZATION TO FORCE BALANCE IN CONTROLLED TRIALS WITH UNKNOWN PREVALENCE OF COVARIATES: APPLICATION TO ALCOHOLISM RESEARCH
MULLER et al.
Alcohol Alcohol 2005;40:124-131.
ABSTRACT
| FULL TEXT
Unhealthy Alcohol Use
Saitz
NEJM 2005;352:596-607.
FULL TEXT
COMBINED THERAPY: WHAT DOES ACAMPROSATE AND NALTREXONE COMBINATION TELL US?
KIEFER and WIEDEMANN
Alcohol Alcohol 2004;39:542-547.
ABSTRACT
| FULL TEXT
Psychiatric Correlates of Gambling in Adolescents and Young Adults Grouped by Age at Gambling Onset
Lynch et al.
Arch Gen Psychiatry 2004;61:1116-1122.
ABSTRACT
| FULL TEXT
PHARMACOTHERAPEUTIC TRIALS IN ADOLESCENT ALCOHOL USE DISORDERS: OPPORTUNITIES AND CHALLENGES
Dawes and Johnson
Alcohol Alcohol 2004;39:166-177.
ABSTRACT
| FULL TEXT
A Polymorphism in the Serotonin Receptor 3A (HTR3A) Gene and Its Association With Harm Avoidance in Women
Melke et al.
Arch Gen Psychiatry 2003;60:1017-1023.
ABSTRACT
| FULL TEXT
Improvements in Hippocampal-Dependent Learning and Decremental Attention in 5-HT3 Receptor Overexpressing Mice
Harrell and Allan
Learn. Mem. 2003;10:410-419.
ABSTRACT
| FULL TEXT
THE ROLE OF ANXIETY IN PREDICTING DRINKING BEHAVIOUR
Sloan et al.
Alcohol Alcohol 2003;38:360-363.
ABSTRACT
| FULL TEXT
Evidence-Based Treatments for Substance Use Disorders
Gold and Brady
Focus 2003;1:115-122.
ABSTRACT
| FULL TEXT
Naltrexone Treatment for Alcohol Dependence
Fuller and Gordis
NEJM 2001;345:1770-1771.
FULL TEXT
Effects of Fluvoxamine on Ethanol-Reinforced Behavior in the Rat
Lamb and Järbe
J. Pharmacol. Exp. Ther. 2001;297:1001-1009.
ABSTRACT
| FULL TEXT
Perspectives on Neuroscience and Behavior
Neuroscientist 2001;7:91-92.
PHARMACOTHERAPY OF ALCOHOLISM: GAPS IN KNOWLEDGE AND OPPORTUNITIES FOR RESEARCH
Kranzler
Alcohol Alcohol 2000;35:537-547.
ABSTRACT
| FULL TEXT
Ondansetron Shows Promise for Helping Control Alcoholism
JWatch Psychiatry 2000;2000:12-12.
FULL TEXT
Ondansetron Shows Promise for Helping Control Alcoholism
JWatch Women's Health 2000;2000:8-8.
FULL TEXT
Ondansetron and Alcoholism
JWatch General 2000;2000:8-8.
FULL TEXT
Ondansetron Shows Promise for Helping Control Alcoholism
JWatch General 2000;2000:3-3.
FULL TEXT
Medications for Alcohol Dependence--New Vistas
Kranzler
JAMA 2000;284:1016-1017.
FULL TEXT
|
